Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA”

162 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 162 results

Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Study completedNCT01802320
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Who this might be right for
Colon Mucinous AdenocarcinomaColon Signet Ring Cell AdenocarcinomaRectal Mucinous Adenocarcinoma+13 more
National Cancer Institute (NCI) 18
Not applicableNo Longer AvailableNCT03317366
What this trial is testing

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Who this might be right for
Proteus SyndromePIK3CA-Related Overgrowth Spectrum (PROS)Growth Disorders
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Large-scale testing (Phase 3)Active Not RecruitingNCT06764186
What this trial is testing

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
AstraZeneca 101
Early research (Phase 1)Active Not RecruitingNCT03006172
What this trial is testing

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Who this might be right for
Breast CancerSolid Tumor
Genentech, Inc. 200
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Testing effectiveness (Phase 2)Looking for participantsNCT06463028
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Faeth Therapeutics 40
Not applicableStudy completedNCT07222423
What this trial is testing

The Epidemiology and Hospital Management of Patients With PROS in France

Who this might be right for
PIK3CA-Related Overgrowth Spectrum
Novartis Pharmaceuticals 3,605
Testing effectiveness (Phase 2)Ended earlyNCT03290092
What this trial is testing

Trial of Taselisib in Overgrowth

Who this might be right for
PIK3CA-Related Overgrowth
Centre Hospitalier Universitaire Dijon 19
Not applicableStudy completedNCT04480814
What this trial is testing

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC

Who this might be right for
Breast Cancer
Pharmassist Ltd 30
Not applicableStudy completedNCT05022342
What this trial is testing

Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 595
Not applicableStudy completedNCT02449564
What this trial is testing

The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors

Who this might be right for
Solid Tumor
Samsung Medical Center 5
Testing effectiveness (Phase 2)Study completedNCT01625286
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

Who this might be right for
Advanced or Metastatic Breast CancerER+ve Advanced or Metastatic Breast Cancer
AstraZeneca 148
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Testing effectiveness (Phase 2)Ended earlyNCT01602315
What this trial is testing

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Novartis Pharmaceuticals 179
Not applicableStudy completedNCT03951389
What this trial is testing

INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer

Who this might be right for
Colon Cancer
New Mexico Cancer Research Alliance 750
Testing effectiveness (Phase 2)Study completedNCT04495621
What this trial is testing

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Who this might be right for
Metastatic Colorectal Cancer
Menarini Group 29
Early research (Phase 1)Study completedNCT03317119
What this trial is testing

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Who this might be right for
Metastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Carcinoma+22 more
City of Hope Medical Center 26
Testing effectiveness (Phase 2)Ended earlyNCT04409145
What this trial is testing

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Who this might be right for
Venous MalformationLymphatic MalformationVenolymphatic Malformation
Venthera, Inc., a BridgeBio company 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07441512
What this trial is testing

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Who this might be right for
TNBC - Triple-Negative Breast CancerTNBC
Hu Hai 26
Load More Results